Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV000672644 | SCV004190871 | pathogenic | Maple syrup urine disease | 2023-02-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000672644 | SCV004398160 | pathogenic | Maple syrup urine disease | 2022-12-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the DBT protein in which other variant(s) (p.Met477Arg) have been determined to be pathogenic (PMID: 20307994; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 556615). This variant has not been reported in the literature in individuals affected with DBT-related conditions. This variant is present in population databases (rs749366506, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Trp448*) in the DBT gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 35 amino acid(s) of the DBT protein. |
Counsyl | RCV000672644 | SCV000797769 | uncertain significance | Maple syrup urine disease | 2018-02-16 | flagged submission | clinical testing |